Emphasis on the management of embedded capsular hyperplasia nodules associated with benign prostatic hyperplasia

Abstract

Benign prostatic hyperplasia is commonly observed in older men, and surgery is the primary treatment. Management of prostatic hyperplasia nodules, especially embedded capsular hyperplasia nodules, is crucial for reducing the incidence of postoperative complications and the need for repeat surgery. We summarize the sources of prostatic hyperplasia nodules, relationship between the nodules and the surgical capsule of the prostate, advantages and disadvantages of various surgical procedures for hyperplasia nodules, and impact of surgery on the incidence of postoperative complications. Additionally, we share our experience with the management of embedded capsular hyperplasia nodules using thulium laser enucleation of the prostate. We hope that doctors will pay attention to the management of embedded capsular hyperplasia nodules during prostate surgery in their clinical practice.

Keywords

Benign prostatic hyperplasia / Surgical capsule / Hyperplasia nodule

Acknowledgments

None.

Statement of ethics

Ethics approval was waived for this retrospective analysis.

Conflict of interest statement

SX is the editor-in-chief of Current Urology, confirms no involvement in any stage of this article's peer-review process, ensuring unbiased editorial decision-making. This article was accepted after a normal external review. No conflict of interest has been declared by the other authors.

Funding source

None.

Author contributions

CZ and YZ collected the article data and wrote this article; CZ and YJ provide the collected all clinical data and graphs; SX supervised all the research process and did the revision of this article.

Data availability

The datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding authors on reasonable request.

References

[1] Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I—Initial work-up and medical management. J Urol 2021; 206(4):806-817.

[2] Gravas S, Gacci M, Gratzke C, et al. Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms. Eur Urol 2023; 84(2):207-222.

[3] Filomena GB, Gentile BC, Albanesi L, et al. Long-term outcomes following bipolar transurethral plasma enucleation of the prostate:10-Year follow-up. J Endourol 2023; 37(7):811-816.

[4] Maclennan GT, Cheng L. Prostate. In: Atlas of Genitourinary Pathology. London: Springer; 2011:215-283.

[5] Cannon GW, Getzenberg RH. Biomarkers for benign prostatic hyperplasia progression. Curr Urol Rep 2008; 9(4):279-283.

[6] Zhu Z, Kang J. Review on the recent research progress of benign prostatic hyperplasia [in Chinese]. J Clin Urol (China) 2019; 34(05):409-412.

[7] Stewart BD, Nascimento AF. Palmar and plantar fibromatosis: A review. J Pathol Transl Med 2021; 55(4):265-270.

[8] Wu D, Chen Z. Application of MRI in the diagnosis of prostate diseases and its progress [in Chinese]. J Clin Radiol 2010; 29(2):274-276.

[9] Strand DW, Costa DN, Francis F, Ricke WA, Roehrborn CG. Targeting phenotypic heterogeneity in benign prostatic hyperplasia. Differentiation 2017;96:49-61.

[10] Zhang SJ, Qian HN, Zhao Y, et al. Relationship between age and prostate size. Asian J Androl 2013; 15(1):116-120.

[11] Bierhoff E, Vogel J, Benz M, Giefer T, Wernert N, Pfeifer U. Stromal nodules in benign prostatic hyperplasia. Eur Urol 1996; 29(3):345-354.

[12] Xia SJ, Zhuo J, Sun XW, Han BM, Shao Y, Zhang YN. Thulium laser versus standard transurethral resection of the prostate: A randomized prospective trial. Eur Urol 2008; 53(2):382-389.

[13] Huang H. Surgery. Chinese Guidelines for the Diagnosis and Treatment of Urologic and Male Diseases: 2019 Edition. Beijing, China: Science and Technology Press; 2020:207-208.

[14] Woo H, Levin R, Cantrill C, et al. Prospective trial of water vapor thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia in subjects with a large prostate: 6- and 12-month outcomes. Eur Urol Open Sci 2023;58:64-72.

[15] Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)—Incidence, management, and prevention. Eur Urol 2006; 50(5):969-979.

[16] Cornu JN, Ahyai S, Bachmann A, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: An update. Eur Urol 2015; 67(6):1066-1096.

[17] Kim A, Hak AJ, Choi WS, Paick SH, Kim HG, Park H. Comparison of long-term effect and complications between holmium laser enucleation and transurethral resection of prostate: Nations-wide health insurance study. Urology 2021;154:300-307.

[18] Morozov A, Taratkin M, Shpikina A, et al. Comparison of EEP and TURP long-term outcomes: Systematic review and meta-analysis. World J Urol 2023; 41(12):3471-3483.

[19] Seaman EK, Jacobs BZ, Blaivas JG, Kaplan SA. Persistence or recurrence of symptoms after transurethral resection of the prostate: A urodynamic assessment. J Urol 1994; 152(3):935-937.

[20] Kuo HC. Analysis of the pathophysiology of lower urinary tract symptoms in patients after prostatectomy. Urol Int 2002; 68(2):99-104.

[21] Pandolfo SD, Crauso F, Aveta A, et al. A novel low-cost uroflowmetry for patient telemonitoring. Int J Environ Res Public Health 2023; 20(4):3287.

[22] Enikeev D, Taratkin M, Morozov A, et al. Long-term outcomes of holmium laser enucleation of the prostate: A 5-year single-center experience. J Endourol 2020; 34(10):1055-1063.

[23] Semmens JB, Wisniewski ZS, Bass AJ, Holman CD, Rouse IL. Trends in repeat prostatectomy after surgery for benign prostate disease: Application of record linkage to healthcare outcomes. BJU Int 1999; 84(9):972-975.

[24] Elshal AM, Elmansy HM, Elhilali MM. Feasibility of holmium laser enucleation of the prostate (HoLEP) for recurrent/residual benign prostatic hyperplasia (BPH). BJU Int 2012; 110(11 Pt C):E845-E850.

[25] Woo H, Thangasamy I, Chalasani V. Photoselective vaporization with the green light laser vs transurethral resection of the prostate for treating benign prostate hyperplasia: A systematic review and meta-analysis. BJU Int 2013; 111(4):E137.

[26] Ottaiano N, Shelton T, Sanekommu G, Benson CR. Surgical complications in the management of benign prostatic hyperplasia treatment. Curr Urol Rep 2022; 23(5):83-92.

[27] Bhat A, Blachman-Braun R, Herrmann TRW, Shah HN. Are all procedures for benign prostatic hyperplasia created equal? A systematic review on post-procedural PSA dynamics and its correlation with relief of bladder outlet obstruction. World J Urol 2022; 40(4):889-905.

[28] Wei D, Wang J, Wan B, Deng S, Zhu S, Zhong C. Causes and management of readmission after prostatectomy for BPH (report of 106 cases) [in Chinese]. Zhonghua Miniao Waike Zazhi 2004; 25(3):187-190.

[29] Tao L, Chen Y, Kong J, et al. The influence of prostate capsule on transurethral resection of the prostate with large volume [in Chinese]. Zhongguo Nankexue Zazhi 2015; 9(11):41-44.

[30] Ditonno F, Manfredi C, Licari LC, et al. Benign prostatic hyperplasia surgery: A snapshot of trends, costs, and surgical retreatment rates in the USA. Eur Urol Focus 2024; 10(5):826-832.

[31] Fu W, Zhang H, Li X, et al. The key points of transurethral plasmakinetic lobulated enucleation of the prostate and prevention of complications [in Chinese]. Xiandai Miniao Waike Zazhi 2019; 24(11):881-884.

[32] Kim TH, Song PH. Anatomical endoscopic enucleation of the prostate for bladder outlet obstruction: A narrative review. J Yeungnam Med Sci 2022; 39(1):12-17.

[33] Ou W, Wang Y, Gao Q, Tao X, Liu B. Efficacy of transurethral thulium laser enucleation versus plasma enucleation for the treatment of prostatic hyperplasia [in Chinese]. Zhongguo Laonianxue Zazhi 2022; 42(20):5019-5023.

[34] Jiang DG, Pang J, XIAO C, et al. Randomized controlled trial comparing between 1470 nm diode laser enucleation of the prostate and plasmakinetic enucleation of the prostate for treating benign prostatic hyperplasia [in Chinese]. J Clin Urol (China) 2017; 32(12):908-911.]

[35] Zhuo J, Wei HB, Zhang F, et al. Two-micrometer thulium laser resection of the prostate-tangerine technique in benign prostatic hyperplasia patients with previously negative transrectal prostate biopsy. Asian J Androl 2017; 19(2):244-247.

[36] Pandolfo SD, Del Giudice F, Chung BI, et al. Robotic assisted simple prostatectomy versus other treatment modalities for large benign prostatic hyperplasia: A systematic review and meta-analysis of over 6500 cases. Prostate Cancer Prostatic Dis 2023; 26(3):495-510.

[37] Wang X, Pan J, Zhang X, et al. Clinical comparison between thulium laser transurethral enucleation of the prostate and green laser transurethral enucleation of the prostate in the treatment of benign prostatic hyperplasia. J Clin Urol (China) 2023; 38(5):342-346.

[38] Liu SY, Yang BY, Xia SJ, Qian YX. The relationship between surgical strategies for benign prostatic hyperplasia and complications. Zhonghua Yi Xue Za Zhi 2020; 100(26):2009-2011.

[39] Cantiello F, Crocerossa F, Alba S, et al. Refining surgical strategies in ThuLEP for BPH: A propensity score matched comparison of en-bloc, three lobes, and two lobes techniques. World J Urol 2024; 42(1):431.

[40] Zhou D, Shi Y, Cao T, et al. Thulium laser enucleation of the prostate with “three grooves and two arcs” for the treatment of high-risk and large-volume BPH in the elderly. J Minim Invasive Urol 2023; 12(2):102-105.